UNICLONE
DEAD

Serial Number

78131079

Owner

Protagen AG

Attorney

Jennifer Fraser

Filing Date

May 24, 2002

Add to watchlist:

No watchlists yet
View on USPTO

UNICLONE Trademark

Serial Number: 78131079 • Registration: 2771609

UNICLONE is a trademark filed by Protagen AG on May 24, 2002. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Protagen AG (3 trademarks)

Otto-Hahn-Str. 15
DORTMUND 44227 , DE

Entity Type: 99

Trademark Details

Filing Date

May 24, 2002

Registration Date

October 7, 2003

Published for Opposition

July 15, 2003

Cancellation Date

May 9, 2014

Goods & Services

Scientific devices and instruments for the protein-expression in a protein-expression bank, namely, protein-biochips, comprising clones for identification and validation of proteins and encoding nucleicacids together with expression-vectors thereof

Pharmaceutical and veterinarian preparations containing therapeutic proteins, therapeutic nucleicacids, gene and/or cells for health and medical care, namely, for the treatment of allergies, arthritis, cancer, diabetes, diseases of the central nervous system, inflammatory diseases, metabolic disorders, viral diseases; pharmaceutical preparations for use in cardiology and oncology; medical and pharmaceutical products, namely human vaccines, anti-infectives, diagnostic proteins, therapeutic proteins, therapeutic nucleicacids, gene and/or cells; medical, biotechnological and gene-technological products and preparations obtainable by protein-expression-banks and nucleicacid-banks together with expression-vectors, proteomics, proteome-analysis, biochips, comprising proteins and nucleicacids, protein-biochips, arrays for use in or at human beings or animals, namely, proteins; diagnostics and detergents for medical and veterinarian use, namely diagnostic preparations and reagents for clinical or medical laboratory use

Services for chemical, pharmaceutical, biotechnological, diagnostical, analytical, gene-technological, medical laboratories or industrial facilities or research- and development facilities, namely consulting and analysis in the field of chemistry, pharmacy, biotechnology, diagnostic, analytical, gene-technology, bio-informatics, target validation and drug development, by means of nucleicacid- or protein-biochips, protein-expression-banks, nucleicacid-banks, polypeptide or nucleicacid-libraries and arrays, automation, application and use of protein-biochips; consulting and analysis in the field of automation, application and use of proteomics, proteome studies, proteome designs, peptide and protein analytic and identification, purification and characterization, 1 D and 2D gele electrophorese, mass spectrometry, robotics for proteomics and protein-expression-banks

Filing History

CANCELLED SEC. 8 (10-YR)/EXPIRED SECTION 9
May 9, 2014 CAEX
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Oct 22, 2009 C15A
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Oct 22, 2009 APRE
TEAS SECTION 8 & 15 RECEIVED
Oct 7, 2009 E815
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Oct 7, 2009 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Oct 7, 2009 COAR
CASE FILE IN TICRS
Jul 18, 2008 CFIT
REGISTERED-PRINCIPAL REGISTER
Oct 7, 2003 R.PR
PUBLISHED FOR OPPOSITION
Jul 15, 2003 PUBO
NOTICE OF PUBLICATION
Jun 25, 2003 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 24, 2003 CNSA
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 21, 2003 CRFA
PAPER RECEIVED
Mar 21, 2003 MAIL
NON-FINAL ACTION E-MAILED
Jan 8, 2003 GNRT
ASSIGNED TO EXAMINER
Oct 11, 2002 DOCK
ASSIGNED TO EXAMINER
Sep 19, 2002 DOCK